Worldquant Millennium Advisors LLC Has $41.11 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Worldquant Millennium Advisors LLC lifted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 31.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 315,221 shares of the life sciences company's stock after purchasing an additional 74,627 shares during the period. Worldquant Millennium Advisors LLC owned 0.20% of Illumina worth $41,108,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina in the 2nd quarter valued at about $34,000. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. bought a new stake in shares of Illumina during the 2nd quarter valued at $61,000. Private Trust Co. NA lifted its stake in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after purchasing an additional 212 shares during the period. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Illumina in the 2nd quarter valued at $63,000. Institutional investors own 89.42% of the company's stock.

Illumina Stock Up 0.8 %

Shares of NASDAQ ILMN traded up $1.18 during trading hours on Friday, hitting $141.09. The company had a trading volume of 1,106,683 shares, compared to its average volume of 2,073,166. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The firm's 50 day moving average is $142.90 and its 200-day moving average is $126.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.33 earnings per share. Analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of recent analyst reports. Robert W. Baird upped their price objective on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Daiwa America upgraded shares of Illumina to a "strong-buy" rating in a research report on Friday, August 16th. Argus upgraded shares of Illumina from a "hold" rating to a "buy" rating and set a $150.00 price objective for the company in a report on Wednesday, August 28th. HSBC upgraded shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Finally, Daiwa Capital Markets upgraded shares of Illumina from a "neutral" rating to a "buy" rating and upped their price objective for the company from $120.00 to $154.00 in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Illumina currently has a consensus rating of "Moderate Buy" and an average target price of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.